Axsome Therapeutics to Participate in Investor Conferences in September

Axsome Therapeutics to Participate in Investor Conferences in September

August 27, 2024 | Last Trade: US$82.57 1.21 -1.44

Morgan Stanley 22^nd Annual Global Healthcare Conference on September 4 in New York
Wells Fargo Healthcare Conference on September 5 in Boston
Baird 2024 Global Healthcare Conference on September 11 in New York
Cantor Global Healthcare Conference on September 18 in New York

NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, will participate in four investor conferences in September:

Morgan Stanley 22^nd Annual Global Healthcare Conference
The Company will present on Wednesday, September 4, 2024 at 4:50 p.m. ET in New York, NY

2024 Wells Fargo Healthcare Conference
The Company will participate in investor meetings on Thursday, September 5, 2024 in Boston, MA

Baird 2024 Global Healthcare Conference
The Company will present on Wednesday, September 11, 2024 at 8:30 a.m. ET in New York, NY

2024 Cantor Global Healthcare Conference
The Company will present on Wednesday, September 18, 2024 at 9:45 a.m. ET in New York, NY

Live webcasts of the presentations at the Morgan Stanley and Cantor conferences can be accessed on the Investors page of the Company’s website at www.axsome.com. Replays of the webcasts will be available for approximately 30 days following each event.

About Axsome Therapeutics

Axsome Therapeutics, Inc. is a biopharmaceutical company developing and delivering novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. At Axsome, we are committed to developing products that meaningfully improve the lives of patients and provide new therapeutic options for physicians. For more information, please visit the Company’s website at www.axsome.com.

Investors:
Mark Jacobson
Chief Operating Officer
(212) 332-3243
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media:
Darren Opland
Director, Corporate Communications
(929) 837-1065
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Last Trade:	US$82.57
Daily Change:	-1.21 -1.44
Daily Volume:	688,508
Market Cap:	US$4.000B

December 30, 2024 Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation November 26, 2024 Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy November 12, 2024 Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update November 08, 2024 Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024 October 29, 2024 Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024 LOAD MORE NEWS

Featured Stock

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE